Liraglutide safety, tolerability, and pharmacokinetics investigated in obese adolescents with Type 2 Diabetes

Type 2 Diabetes (T2D) in pediatric patients is a growing concern, often associated with obesity and carrying significant long-term health risks. Treatment options for pediatric T2D are limited, with metformin being the primary oral agent. There's a critical need for safe and effective adjunctive therapies to improve glycemic control and manage comorbidities in this vulnerable population. Liraglutide, a GLP-1R agonist, has demonstrated efficacy and safety in adults with T2D and obesity, making it a promising candidate for pediatric use, but its specific profile in children requires dedicated investigation.

This was a Phase 1, randomized, double-blind, placebo-controlled clinical trial (NCT01789086) conducted in Europe and the USA. The study enrolled 21 obese adolescent subjects aged 12 to 17 years. Participants received multiple daily subcutaneous (SC) doses of Liraglutide or placebo. The primary endpoint was the Number of Treatment Emergent Adverse Events (TEAEs), assessing the safety and tolerability of the compound. Secondary objectives included evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of Liraglutide in this pediatric population, determining drug concentration over time and its effects on glucose and insulin.

This Phase 1 study primarily aimed to establish the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of Liraglutide in pediatric patients. The primary objective was to determine the Number of Treatment Emergent Adverse Events (TEAEs), a crucial measure for drug safety. The study also investigated the PK of Liraglutide, assessing its absorption, distribution, metabolism, and excretion in the pediatric population by measuring blood concentrations over time to understand drug exposure. Furthermore, PD were evaluated to understand the drug's effects on relevant biomarkers, such as glucose and insulin levels. While the trial completed, suggesting data was collected, the provided abstract does not detail specific numerical results, statistical outcomes, or incidence rates of TEAEs, nor does it present specific PK/PD parameters. The study's completion indicates that a safety and exposure profile was generated for Liraglutide in this vulnerable patient group, but the concrete findings are not available in this summary.